Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
How to prepare for the Fed's forthcoming interest rate cuts
Recommended
The sun now sets before 8 p.m. Will we ever do away with the time change?
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eisai Ltd ADR
(OP:
ESALY
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EST, Jan 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
61.51
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
April 24, 2024
Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA...
Via
Benzinga
Exposures
Product Safety
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
March 22, 2024
Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling.
Via
Benzinga
Performance
More News
Read More
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
March 08, 2024
Via
Benzinga
Exposures
Product Safety
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
February 14, 2024
Via
Benzinga
Why Is Biogen Stock Trading Lower On Tuesday?
February 13, 2024
Via
Benzinga
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
January 12, 2024
Via
Benzinga
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
December 08, 2023
Via
Benzinga
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
November 21, 2023
Via
Benzinga
Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides
November 08, 2023
Via
Benzinga
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
October 13, 2023
Via
Benzinga
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
October 11, 2023
Via
Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
October 10, 2023
Via
Benzinga
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
September 25, 2023
Via
Benzinga
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
September 25, 2023
Via
Benzinga
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
September 22, 2023
Via
Benzinga
Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
August 25, 2023
Via
Benzinga
Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.
August 01, 2023
Via
The Motley Fool
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
July 10, 2023
Via
MarketBeat
Exposures
Product Safety
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
July 07, 2023
Via
Benzinga
Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed
June 14, 2023
Via
Benzinga
FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories
June 13, 2023
Via
Benzinga
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
June 13, 2023
Via
Benzinga
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
June 12, 2023
Via
Benzinga
Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low
June 12, 2023
Via
Benzinga
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
June 08, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.